Authors:
Thevenot, T
Regimbeau, C
Ratziu, V
Leroy, V
Opolon, P
Poynard, T
Citation: T. Thevenot et al., Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update, J VIRAL HEP, 8(1), 2001, pp. 48-62
Authors:
Ducimetiere, P
Signeyrole, D
Giral, P
Hoog-Labouret, N
Amarenco, P
Chanu, B
Chauvenet, M
Coletti, M
Dallongeville, J
Durlach, V
Kawka, G
Krempf, M
Leroux, G
Mlika-Cabanne, N
Monnier, L
Paillard, F
Rostoker, G
Sicard, D
Verny, C
Voiriot, P
Acquart, B
Alquier, G
Ankri, J
Badoc, G
Basdevant, A
Belmin, J
Berthezene, F
Beucler, I
Blanc, F
Broustet, JP
Bruckert, E
Brun, JM
Castaigne, A
Charpentier, JM
Andre, MC
Cogneau, J
Demeaux, JL
Denolle, T
Desson, JF
Drahi, E
Drouin, P
Dumel, F
Emmerich, J
Farnier, M
Fontbonne, A
Forette, B
Gambert, P
Gautier, JC
Guillausseau, PJ
Hommel, M
Janowski, M
Le Goaziou, MF
Lievre, M
Le Quere, M
Leys, D
Marechaud, R
Mas, JL
Menard, J
Michel, JM
Mounier-Vehier, F
Mottier, D
Passa, P
Pinel, JF
Puel, J
Raccah, D
Renou, P
Ribier, A
Schlienger, JL
Thomas, D
Vallee, JP
Veyssier-Belot, C
Bouvenot, G
Abadie, E
Alexandre, JM
Belorgey-Bismut, C
Bergmann, JF
Camelli, B
Caulin, C
Costagliola, D
Denis, C
Dupuis, B
Fleurette, F
Guillevin, L
Hoog-Labouret, N
Paintaud, G
Rauss, A
Poynard, T
Rostoker, G
Wong, O
Citation: P. Ducimetiere et al., The AFSSAPS recommendations for good practice: Therapeutic management of patients with dyslipidemia., J MAL VASC, 26(2), 2001, pp. 105-110
Authors:
Benhamou, Y
Di Martino, V
Bochet, M
Colombet, G
Thibault, V
Liou, A
Katlama, C
Poynard, T
Citation: Y. Benhamou et al., Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy, HEPATOLOGY, 34(2), 2001, pp. 283-287
Citation: T. Poynard et al., Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, ALIM PHARM, 15(3), 2001, pp. 355-361
Authors:
Poynard, T
Ratziu, V
Charlotte, F
Goodman, Z
McHutchison, J
Albrecht, J
Citation: T. Poynard et al., Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C, J HEPATOL, 34(5), 2001, pp. 730-739
Authors:
Neuman, MG
Brenner, DA
Rehermann, B
Taieb, J
Chollet-Martin, S
Cohard, M
Garaud, JJ
Poynard, T
Katz, GG
Cameron, RG
Shear, NH
Gao, B
Takamatsu, M
Yamauchi, M
Ohata, M
Saito, S
Maeyama, S
Uchikoshi, T
Toda, G
Kumagi, T
Akbar, SMF
Abe, M
Michitaka, K
Horlike, N
Onji, M
Citation: Mg. Neuman et al., Mechanisms of alcoholic liver disease: Cytokines, ALC CLIN EX, 25(5), 2001, pp. 251S-253S
Authors:
Benhamou, Y
Bochet, M
Thibault, V
Calvez, V
Fievet, MH
Vig, P
Gibbs, CS
Brosgart, C
Fry, J
Namini, H
Katiama, C
Poynard, T
Citation: Y. Benhamou et al., Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study, LANCET, 358(9283), 2001, pp. 718-723
Authors:
Imbert-Bismut, F
Ratziu, V
Pieroni, L
Charlotte, F
Benhamou, Y
Poynard, T
Citation: F. Imbert-bismut et al., Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study, LANCET, 357(9262), 2001, pp. 1069-1075
Authors:
Pieroni, L
Khalil, L
Charlotte, F
Poynard, T
Piton, A
Hainque, B
Imbert-Bismut, F
Citation: L. Pieroni et al., Comparison of bathophenanthroline sulfonate and ferene as chromogens in colorimetric measurement of low hepatic iron concentration, CLIN CHEM, 47(11), 2001, pp. 2059-2061
Authors:
Mathurin, P
Thibault, V
Kadidja, K
Ganne-Carrie, N
Moussalli, J
El Younsi, M
Di Martino, V
Lunel, F
Charlotte, F
Vidaud, M
Opolon, P
Poynard, T
Citation: P. Mathurin et al., Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections, J VIRAL HEP, 7(1), 2000, pp. 15-22
Authors:
Poynard, T
McHutchison, J
Davis, GL
Esteban-Mur, R
Goodman, Z
Bedossa, P
Albrecht, J
Citation: T. Poynard et al., Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C, HEPATOLOGY, 32(5), 2000, pp. 1131-1137
Authors:
Poynard, T
McHutchison, J
Goodman, Z
Ling, MH
Albrecht, J
Citation: T. Poynard et al., Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?, HEPATOLOGY, 31(1), 2000, pp. 211-218
Authors:
Taieb, J
Mathurin, P
Elbim, C
Cluzel, P
Arce-Vicioso, M
Bernard, B
Opolon, P
Gougerot-Pocidalo, MA
Poynard, T
Chollet-Martin, S
Citation: J. Taieb et al., Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids, J HEPATOL, 32(4), 2000, pp. 579-586
Authors:
Wong, JB
McQuillan, GM
McHutchison, JG
Poynard, T
Citation: Jb. Wong et al., Estimating future hepatitis C morbidity, mortality, and costs in the United States, AM J PUB HE, 90(10), 2000, pp. 1562-1569
Authors:
Allory, Y
Charlotte, F
Benhamou, Y
Opolon, P
Le Charpentier, Y
Poynard, T
Citation: Y. Allory et al., Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case-control study, HUMAN PATH, 31(1), 2000, pp. 69-74
Authors:
Zylberberg, H
Benhamou, Y
Lagneaux, JL
Landau, A
Chaix, ML
Fontaine, H
Bochet, M
Poynard, T
Katlama, C
Pialoux, G
Brechot, C
Pol, S
Citation: H. Zylberberg et al., Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIVcoinfected subjects: an early report, GUT, 47(5), 2000, pp. 694-697
Authors:
McHutchison, JG
Poynard, T
Pianko, S
Gordon, SC
Reid, AE
Dienstag, J
Morgan, T
Yao, RJ
Albrecht, J
Citation: Jg. Mchutchison et al., The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C, GASTROENTY, 119(5), 2000, pp. 1317-1323